Post-traumatic stress disorder: New directions in pharmacotherapy

As many as 10% of the population experience post-traumatic stress disorder (PTSD) at some time in their lives. It often runs a severe, chronic and treatment-resistant course. This article reviews the evidence base for typically recommended treatments such as cognitive–behavioural therapy (CBT), eye movement desensitisation and reprocessing and selective serotonin reuptake inhibitors (SSRIs). It tabulates the major randomised controlled trials of SSRIs and trauma-focused CBT and reviews research on novel treatments such as ketamine, MDMA, quetiapine, propranolol and prazosin.

Journal

English

Ben Green

Green, B. (2013). Post-traumatic stress disorder: New directions in pharmacotherapy. Advances in Psychiatric Treatment, 19, 181-190. doi:10.1192/apt.bp.111.010041